Cancer Profiling  Market to Expand  at a Healthy CAGR of  17.7%  through  2031

Key Takeaways from Market Study

– By indication, non-small cell lung cancer (NSCLC) is likely to aggrandize impressively through 2031 – Fluorescence in-situ hybridization (FISH) instruments to experience high sales – The U.S. to experience heightened growth amid increasing cancer prevalence amongst the population – Robust institutional frameworks to accelerate oncology research pivoting cancer profiling expansion across Germany – India to emerge as a heavyweight in the cancer profiling market, attributed to increasing prevalence in the wake of an exponential population upswing

Key Market Segments Covered

– Product InstrumentsImmunohistochemistry (IHC) Analyzers Fluorescence in-situ Hybridization (FISH) Instruments PCR Instruments DNA Sequencer Fragment Analyzer ConsumablesReagents & Kits Other Ancillary (Probes, Holders, etc.) – IndicationBreast Cancer Colorectal Cancer Ovarian Cancer Melanoma Kidney Cancer Lung Cancer (including NSCLC) Rare Cancers – TestImmunohistochemistry (IHC) Fluorescence in-situ Hybridization (FISH) Qualitative Polymerase Chain Reaction (qPCR) Next Generation Sequencing (NGS) Sanger Testing Fragment Analysis

Key Countries Covered

– US – Canada – EU-4 – UK – BENELUX – Nordics – Brazil – Mexico – Russia – India – ASEAN – South Korea – Australia & New Zealand – Japan

Explore Fact.MR's Coverage